

1 May 2018

Australian Securities Exchange
20 Bridge Street,
Sydney NSW 2000

Alcidion Appendix 3Y Notifications

Adelaide, South Australia, 1 May 2018 - Alcidion Group Limited (ASX: **ALC**), has today lodged Appendix 3Y notifications relating to the purchase of shares by the following directors or their associates: Ray Blight (3.02 million shares), Rebecca Wilson (570,000 shares) and Geoff Rohrsheim (1 million shares).

The directors were previously restricted from purchasing shares due to a trading blackout in place whilst the acquisition of MKM Health and Patientrack, announced to the market last week, was being negotiated.

Ray Blight, CEO of Alcidion Group said, "I am pleased to increase my position as a shareholder, and to welcome two of our Directors as fellow shareholders of the company. It has been their intention to buy shares and, now that trading restrictions have been lifted, they have promptly followed through with this. The MKM acquisition is transformative and we look forward to presenting to investors at our roadshow underway this week."

ENDS

For further information, please contact:

Ray Blight, Chief Executive Officer
Ph: +61 (08) 8208 4600
Alcidion Group Limited
ray.blight@alcidion.com

Kyahn Williamson, WEBuchan
Ph: 0401018828
kwilliamson@we-buchan.com

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion's focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2018. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	RAYMOND HOWARD <u>BLIGHT</u>
Date of last notice	23/12/2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	DIRECT & INDIRECT
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	SHARES HELD BY SPOUSE (ROBYN GAILE MORRIS)
Date of change	24-27 April 2018
No. of securities held prior to change	97,051,004
Class	FULLY PAID ORDINARY SHARES
Number acquired	3,020,000
Number disposed	NIL
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$129,172
No. of securities held after change	100,071,004 FULLY PAID ORDINARY SHARES -

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	ON-MARKET TRADES
---	------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

1 May 2018

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	GEOFF ROHRSHEIM
Date of last notice	31/07/2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	G R ROHRSHEIM NOMINEES PTY LTD ATF ROHRSHEIM SUPER FUND
Date of change	26 APRIL 2018
No. of securities held prior to change	NIL
Class	FULLY PAID ORDINARY SHARES
Number acquired	1,000,000 FULLY PAID ORDINARY SHARES
Number disposed	-

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$40,621.15 PAID FOR FULLY PAID ORDINARY SHARES
No. of securities held after change	1,000,000 FULLY PAID ORDINARY SHARES
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	ON-MARKET TRADE

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

ENDS

For further information, please contact:

Duncan Craig

Chief Financial Officer and Company Secretary

Ph: +61 (08) 8208 4600

Alcidion Corporation

duncan.craig@alcidion.com

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion's focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies

1 May 2018

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	REBECCA WILSON
Date of last notice	31/07/2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	DIRECT
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	27 APRIL 2018
No. of securities held prior to change	NIL
Class	FULLY PAID ORDINARY SHARES
Number acquired	570,000 FULLY PAID ORDINARY SHARES
Number disposed	-

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$25,080 PAID FOR FULLY PAID ORDINARY SHARES
No. of securities held after change	570,000 FULLY PAID ORDINARY SHARES
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	ON-MARKET TRADES

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

ENDS

For further information, please contact:

Duncan Craig

Chief Financial Officer and Company Secretary

Ph: +61 (08) 8208 4600

Alcidion Corporation

duncan.craig@alcidion.com

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion's focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies